Arthneeti
All Q1 FY27 results →
IC

IOL Chemicals

Q1 FY27Pharmaceuticals & Biotechnology

IOL Chemicals Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹195
Market cap₹5.7K Cr
P/E32.4
Updated16 Oct 2026
Read4 min read

What the Q1 FY27 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising

The short version

For FY27, the company expects revenue growth of 15% to 20% with EBITDA margin between 14% to 15% (Page 5, 9). FY27 revenue growth guidance: 15% to 20%; EBITDA margin forecasted at 14% to 15%.

From IOL Chemicals's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Moderate growth
  • For FY27, the company expects revenue growth of 15% to 20% with EBITDA margin between 14% to 15% (Page 5, 9).
  • Growth is driven by higher capacity utilization, better product mix, operational efficiencies, and strong demand in domestic and export markets (Page 9).
  • For FY28, a similar growth rate of 15% to 20% in top line and 15% to 17% EBITDA margin is targeted, subject to market conditions (Page 9).
  • Sustainable growth is supported by a diversified and broad-based product portfolio expanding beyond ibuprofen (Page 7, 13).
  • Export contribution is targeted around 25% to 30% of revenue, with potential to move toward 30%+ (Pages 4, 15).

2 more points from IOL Chemicals's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what IOL Chemicals said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • IOL plans a capex of approximately INR 200-250 crores annually, with around 60% directed toward expansion and new product development, and 40% toward infrastructure and efficiency improvements.
  • The company has a 101-acre land parcel for future expansion, with statutory permissions underway.
  • Major new projects on this land are not expected to be commissioned within the current fiscal year (FY27); likely FY28 or FY29 growth platforms.
  • IOL is actively working on R&D initiatives, with investments in advanced analytical equipment (XRD, LCMS, GCMS) to support product development.

2 more points from IOL Chemicals's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what IOL Chemicals said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • IOL Chemicals and Pharmaceuticals Limited has reasonable visibility into their order book for the coming quarter as of Q1 FY27.
  • The company expects sustained demand based on this order book visibility, supporting their confident revenue growth guidance.
  • They anticipate revenue growth of around 15% to 20% with EBITDA margins around 14% to 15% for FY27, indicating a healthy order inflow.

2 more points from IOL Chemicals's call on order book

Create a free account to keep reading this call

IOL Chemicals — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹619 Cr, net profit ₹53 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What IOL Chemicals's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharmaceuticals Ltd (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral Ltd (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules Ltd (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

IOL Chemicals and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were IOL Chemicals Q1 FY27 results?

For FY27, the company expects revenue growth of 15% to 20% with EBITDA margin between 14% to 15% (Page 5, 9). FY27 revenue growth guidance: 15% to 20%; EBITDA margin forecasted at 14% to 15%.

What is IOL Chemicals share price analysis?

IOL Chemicals currently shows a below-average growth signal. The stock trades at a P/E of 32.4 with a market cap of ₹5,715 Cr. Investors should review the full earnings analysis for detailed insights.

Is IOL Chemicals planning capital expenditure?

IOL plans a capex of approximately INR 200-250 crores annually, with around 60% directed toward expansion and new product development, and 40% toward infrastructure and efficiency improvements.

Keep IOL Chemicals on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.